HLTH:AU:AU-VanEck Global Healthcare Leaders ETF (AUD)

ETF | Others |

Last Closing

USD 11.58

Change

+0.02 (+0.17)%

Market Cap

USD 0.06B

Volume

0.01M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

NA

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-20 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
VAS:AU Vanguard Australian Shares

+0.16 (+0.16%)

USD 16.05B
VGS:AU Vanguard MSCI International Sh..

+0.47 (+0.37%)

USD 8.59B
IVV:AU iShares Core S&P 500 AUD

+0.15 (+0.27%)

USD 8.26B
QUAL:AU VanEck Vectors MSCI World ex A..

+0.25 (+0.46%)

USD 6.31B
IOZ:AU Ishares Core S&P/Asx 200

+0.06 (+0.18%)

USD 5.96B
STW:AU SPDR® S&P/ASX 200 Fund

+0.16 (+0.21%)

USD 5.61B
HNDQ:AU BetaShares NASDAQ 100 ETF - Cu..

+0.35 (+0.88%)

USD 4.86B
NDQ:AU Betashares Nasdaq 100

+0.26 (+0.61%)

USD 4.83B
A200:AU BetaShares Australia 200

+0.09 (+0.07%)

USD 4.72B
VTS:AU Vanguard US Total Market Share..

+1.09 (+0.26%)

USD 4.70B

ETFs Containing HLTH:AU

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 12.54% 73% C 73% C
Dividend Return 0.87% 8% B- 7% C-
Total Return 13.41% 66% D+ 71% C-
Trailing 12 Months  
Capital Gain 14.54% 61% D- 70% C-
Dividend Return 0.89% 7% C- 6% D-
Total Return 15.43% 51% F 68% D+
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -0.24% 24% F 41% F
Dividend Return 0.07% 21% F 38% F
Total Return 0.31% 9% A- 7% C-
Risk Return Profile  
Volatility (Standard Deviation) 8.16% 68% D+ 94% A
Risk Adjusted Return 0.86% 21% F 39% F
Market Capitalization 0.06B 14% F 51% F

Annual Financials (AUD)

Quarterly Financials (AUD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.